Dark

Check out our API

EGRX
EAGLE PHARMS INC
stock OTC

EOD

Aug 20, 2025

3.19USD+0.314%(+0.01)341

Pre-market

0.00USD-100.000%(-3.18)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 31, 2022

06:54AM EST Eagle Pharma Says On Track To Support Submission Of Landiolol NDA In Q2 2022 RTTNews

06:51AM EST Eagle Pharmaceuticals On Track To Support Submission Of New Drug Application In Second Quarter 2022 For Landiolol, A Beta-1 Adrenergic Blocker Benzinga

Jan 18, 2022

07:20AM EST Eagle Pharmaceuticals (EGRX) on Tuesday announced the commercial availability of its recently approved drug, Vasopressin, an A-rated generic alternative to Vasostrict, with six-months of marketing exclusivity. RTTNews

06:55AM EST Eagle Pharma Announces Commercial Availability Of Vasopressin, A-rated Generic Alternative To Vasostrict RTTNews

06:51AM EST Eagle Pharmaceuticals Announces Commercial Availability Of Vasopressin Benzinga

Jan 5, 2022

01:43PM EST Eagle Pharmaceuticals Says Vasopressin Shipments Scheduled To Commence Jan. 17, 2022; Says On Track To Submit New Drug Application In H1 2022, Seeking Approval Of Landiolol Benzinga

01:39PM EST Eagle Pharmaceuticals Provides 2022 Business Update and Announces Launch of Vasopressin Business Wire

Jan 3, 2022

04:35PM EST Companies To Participate In JP Morgan Healthcare Conference Jan. 11: Cytokinetics, iTeos, Ultragenyx, Cara Therapeutics, Kiniksa Pharma, Nurix Therapeutics, Neurocrine Biosciences, Berkeley Lights, Sema4, Repare Therapeutics, Terns Pharma, CONMED, Talkspace, Kodiak Sciences, Sotera Health, Eagle Pharma Benzinga

04:30PM EST Eagle Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference Business Wire

Dec 29, 2021

11:29AM EST Eagle Pharmaceuticals Announces FDA Has Determined Co. Has Maintained 180 Days Of Marketin gExclusivity For Recently Approved Vasopressin ANDA Benzinga

11:24AM EST Eagle Pharmaceuticals Receives 180 Days of Marketing Exclusivity for Recently Approved Vasopressin Business Wire

Dec 20, 2021

12:16PM EST Eagle Pharmaceuticals Reports That Par Has Unilaterally Withdrawn Attempt To Halt Launch Of Vasopressin RTTNews

Dec 15, 2021

03:51PM EST Eagle Pharmaceuticals Shares Move Higher; Cantor Fitzgerald Sets $50 Price Target Benzinga

01:55PM EST Eagle Pharma Reports Received FDA Approval For Vasopressin Benzinga

01:54PM EST Eagle Pharmaceuticals Receives FDA Approval for Vasopressin Business Wire

08:03AM EST The Daily Biotech Pulse: Lilly Raises Guidance, Medtronic Gets FDA Warning Letter, Decision Day For Calliditas, Genenta IPO Benzinga

Dec 12, 2021

04:56PM EST The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More Benzinga

Dec 2, 2021

12:02PM EST Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates Benzinga

Nov 22, 2021

06:50AM EST Eagle Pharmaceuticals to Present at Piper Sandler 33rd Annual Healthcare Conference 2021 Business Wire

Nov 9, 2021

11:42AM EST The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data Benzinga

11:29AM EST Eagle Pharmaceuticals Q3 EPS $0.57 Misses $0.83 Estimate, Sales $39.90M Miss $46.40M Estimate Benzinga

11:25AM EST Earnings Scheduled For November 9, 2021 Benzinga

07:08AM EST Eagle Pharmaceuticals Q3 Loss/sjhr $0.43 Vs. EPS $0.51 Last Year RTTNews

06:50AM EST Eagle Pharmaceuticals Reports Third Quarter 2021 Results Business Wire

Oct 28, 2021

05:05PM EDT Eagle Pharmaceuticals to Host Third Quarter 2021 Financial Results on November 9, 2021 Business Wire

Oct 5, 2021

08:01AM EDT The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout Benzinga

Oct 1, 2021

07:56AM EDT The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO Benzinga

Sep 30, 2021

07:43AM EDT The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug Benzinga

Sep 28, 2021

08:18AM EDT The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive Benzinga

08:16AM EDT The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK To Develop Long-Acting HIV Treatments Benzinga

Sep 7, 2021

06:50AM EDT Reminder: Eagle Pharmaceuticals to Host CAL02 Investor Event on September 9, 2021 Business Wire

Sep 1, 2021

05:00PM EDT Eagle Pharmaceuticals to Present at September Healthcare Conferences Business Wire

07:32AM EDT The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering Benzinga

Aug 31, 2021

11:51AM EDT Eagle Pharmaceuticals Wins Vasopressin Patent Trial RTTNews

11:46AM EDT Eagle Pharma Reports District Court Held That Co.'s Proposed Vaspressin Product Does Not Infringe On Any Patents Par Asserted Against Co. Benzinga

11:45AM EDT Eagle Pharmaceuticals Wins Vasopressin Patent Trial Business Wire

06:56AM EDT Eagle Pharma Says U.S. Patent And Trademark Office Grants Additional Patent For Bendamustine Franchise RTTNews

06:51AM EDT Eagle Pharmaceuticals Granted Additional Patent For Bendamustine Franchise Benzinga

Aug 25, 2021

07:30AM EDT The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug Benzinga

06:57AM EDT Eagle Pharma Announces Licensing Deal With Combioxin For Phase 2b/3Development Of CAL02 With Antibiotics RTTNews

06:53AM EDT Eagle Pharmaceuticals Announces Worldwide Licensing Agreement With Combioxin SA For Phase 2b/3 Antitoxin Agent CAL02 In Development For Combination Use With Antibiotics For Treatment Of Severe Pneumonia Benzinga

06:50AM EDT Eagle Pharmaceuticals Announces Worldwide Licensing Agreement with Combioxin SA for Phase 2b/3, Novel First-in-Class Antitoxin Agent CAL02 in Development for Combination Use with Antibiotics for the Treatment of Severe Pneumonia Business Wire

Aug 9, 2021

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

07:07AM EDT Recap: Eagle Pharmaceuticals Q2 Earnings Benzinga

06:58AM EDT Eagle Pharma Q2 Net Income $3.6 Mln Or $0.27/Shr Vs Loss Of $0.3 Mln Or $0.02/shr Last Year RTTNews

06:53AM EDT Eagle Pharmaceuticals Q2 Adj. EPS $0.95 Beats $0.80 Estimate, Sales $48.10M Beat $45.86M Estimate Benzinga

06:52AM EDT Eagle Pharma Announces Licensing Agreement With AOP Orphan For U.S. Commercial Rights To Landiolol RTTNews

06:50AM EDT Eagle Pharmaceuticals Reports Second Quarter 2021 Results Business Wire

06:47AM EDT Eagle Pharmaceuticals Announces Licensing Agreement With AOP Orphan For US Commercial Rights To Landiolol, A Beta-1 Adrenergic Blocker; Co. To Make $5M Upfront Payment And Potential Milestone Payments Benzinga

06:45AM EDT Eagle Pharmaceuticals Announces Licensing Agreement with AOP Orphan for U.S. Commercial Rights to Landiolol, a Beta-1 Adrenergic Blocker Business Wire

04:11AM EDT Earnings Scheduled For August 9, 2021 Benzinga

Aug 8, 2021

10:11AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Jul 28, 2021

04:30PM EDT Eagle Pharmaceuticals to Host Second Quarter 2021 Financial Results on August 9, 2021 Business Wire

Jun 24, 2021

07:01AM EDT Eagle Pharma: FDA Maintains Priority Review For Vasopressin ANDA RTTNews

06:51AM EDT Eagle Pharmaceuticals Announces FDA Maintains Prioritization of ANDA for Vasopressin Benzinga

Jun 22, 2021

10:23AM EDT Eagle Pharmaceuticals: Return On Capital Employed Insights Benzinga

Jun 17, 2021

06:54AM EDT Eagle Pharma Submits Response To Complete Response Letter From FDA For Vasopressin RTTNews

06:50AM EDT Eagle Pharmaceuticals Submits Response to Complete Response Letter from FDA for Vasopressin Benzinga

Jun 4, 2021

10:53AM EDT Return On Capital Employed Overview: Eagle Pharmaceuticals Benzinga

May 26, 2021

05:00PM EDT Eagle Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference 2021 Business Wire

May 11, 2021

05:01PM EDT Eagle Pharmaceuticals To Present At The 2021 RBC Capital Markets Global Healthcare Conference Benzinga

May 10, 2021

07:23AM EDT Eagle Pharmaceuticals, Inc. (EGRX) reported Monday that its first-quarter net loss was $0.4 million or $0.03 per share, narrower than last year's loss of $2.9 million or $0.21 per share. RTTNews

07:10AM EDT Recap: Eagle Pharmaceuticals Q1 Earnings Benzinga

06:56AM EDT Eagle Pharmaceuticals Says TREAKISYM RI 50ml Liquid Formulation Filed With PMDA In Japan RTTNews

06:55AM EDT Eagle Pharma Q1 Net Loss $0.4 Mln Or $0.03 /Shr Vs Loss Of $2.9 Mln Or $0.21/Shr Last Year RTTNews

06:52AM EDT Eagle Pharmaceuticals Q1 EPS $0.24 Misses $0.65 Estimate, Sales $41.20M Miss $45.41M Estimate Benzinga

06:50AM EDT Eagle Pharmaceuticals Reports First Quarter 2021 Results Business Wire

06:47AM EDT Eagle Pharmaceuticals Announces Filing of TREAKISYM Rapid Infusion Liquid Formulation in Japan Benzinga

06:45AM EDT Eagle Pharmaceuticals Announces Filing of TREAKISYM (bendamustine) Rapid Infusion ("RI") Liquid Formulation in Japan Business Wire

04:09AM EDT Earnings Scheduled For May 10, 2021 Benzinga

May 3, 2021

06:54AM EDT Eagle Pharma Appoints Luciana Borio To Board RTTNews

06:50AM EDT Eagle Pharmaceuticals Appoints Former FDA Official and Public Health Expert Dr. Luciana Borio to its Board of Directors Business Wire

Apr 30, 2021

06:51AM EDT Eagle Pharmaceuticals Announces TREAKISYM Ready-to-Dilute Formulation, In Combination With Rituximab For Treatment Of Relapsed Or Refractory Diffuse Large B-cell Lymphoma Receives PMDA Approval In Japan Benzinga

06:50AM EDT Eagle Pharmaceuticals Announces TREAKISYM (bendamustine) Ready-to-Dilute ("RTD") Formulation, in Combination with Rituximab for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma Receives PMDA Approval in Japan Business Wire

Apr 29, 2021

04:30PM EDT Eagle Pharmaceuticals to Host First Quarter 2021 Financial Results on May 10, 2021 Business Wire

Mar 2, 2021

07:02AM EST Eagle Pharmaceuticals: Q4 Earnings Insights Benzinga

06:55AM EST Eagle Pharma Q4 Adj. Net Income $12.8 Mln Or $0.96/shr Vs. Income Of $6.7 Mln Or $0.48/shr Prior Year RTTNews

06:54AM EST Eagle Pharmaceuticals Q4 EPS $0.98 May Not Compare To $(0.17) Estimate, Sales $49.90M Miss $53.16M Estimate Benzinga

06:50AM EST Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results and Provides Pipeline Review Business Wire

03:40AM EST Earnings Scheduled For March 2, 2021 Benzinga

Mar 1, 2021

10:15AM EST Earnings Preview: Eagle Pharmaceuticals Benzinga

Feb 27, 2021

09:04PM EST The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings Benzinga

Feb 22, 2021

04:30PM EST Eagle Pharmaceuticals to Host Fourth Quarter and Full Year 2020 Financial Results and Pipeline Review on March 2, 2021 Business Wire

Feb 2, 2021

08:06AM EST Eagle Pharmaceuticals Inc. (EGRX) said Tuesday that it has received a complete response letter or CRL from the U.S. Food and Drug Administration for its Abbreviated New Drug Application or "ANDA" for vasopressin. RTTNews

07:45AM EST FDA Rejects Eagle Pharma's Vasopressin Application Benzinga

07:01AM EST Eagle Pharma Gets Addl FDA Questions Regarding Vasopressin; Court Date Set For July 7 In Vasopressin Trial RTTNews

06:56AM EST Eagle Pharmaceuticals Receives Additional FDA Questions Regarding Vasopressin; Court Date Set for July 7, 2021 in Vasopressin Trial Benzinga

Feb 1, 2021

07:43AM EST Eagle Pharma : US Court Postpones Feb 1 Vasopressin Trial Between Eagle And Endo Par RTTNews

06:52AM EST Eagle Pharmaceuticals Announces Update in Vasopressin Trial; Trial Date Postponed Benzinga

Jan 11, 2021

07:13AM EST Eagle Pharma Updates On Vasopressin Trial, Says Trial Date Postponed To Feb. 1 From Jan. 11 Due To COVID-19 Concerns RTTNews

06:53AM EST Eagle Pharma Says its Vasopressing Trial Will Be Delayed From Jan 11 to Feb 1 Due to COVID-19 Safety Concerns Benzinga

06:50AM EST Eagle Pharmaceuticals Announces Update in Vasopressin Trial; Trial Date Postponed from January 11, 2021 to February 1, 2021 to Protect Against COVID-19 Concerns Business Wire

Jan 4, 2021

04:31PM EST Eagle Pharmaceuticals To Present At 39th Annual J.P. Morgan Healthcare Conference Wed. Jan. 13 At 4:30 p.m. ET Benzinga

04:30PM EST Eagle Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference Business Wire

Nov 23, 2020

06:50AM EST Eagle Pharmaceuticals' Presentation at Piper Sandler 32nd Annual Virtual Healthcare Conference Available for Viewing Business Wire

Nov 2, 2020

08:24AM EST Eagle Pharmaceuticals: Q3 Earnings Insights Benzinga

07:55AM EST Earnings Scheduled For November 2, 2020 Benzinga

06:57AM EST Eagle Pharmaceuticals Q3 EPS $0.51 Vs Loss $0.17 Last Year RTTNews

06:53AM EST Eagle Pharmaceuticals Q3 EPS $1.17 Up From $0.26 YoY, Sales $49.93M Beat $47.02M Estimate Benzinga

06:47AM EST Eagle Pharmaceuticals Reports Third Quarter 2020 Results Business Wire

06:45AM EST Eagle Pharmaceuticals Promotes Brian Cahill as Eagle's New Chief Financial Officer Benzinga

06:45AM EST Eagle Pharmaceuticals Strengthens Management Team to Prepare for Future Growth Business Wire

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 26, 2020

04:30PM EDT Eagle Pharmaceuticals to Discuss Third Quarter 2020 Financial Results on November 2, 2020 Business Wire

Sep 24, 2020

07:01AM EDT Eagle Pharmaceuticals Commences $25 Mln Accelerated Share Repurchase RTTNews

06:51AM EDT Eagle Pharmaceuticals Commences $25M Accelerated Buyback as Part of Existing $160M Buyback Benzinga

06:50AM EDT Eagle Pharmaceuticals Commences $25 Million Accelerated Share Repurchase as Part of Existing $160 Million Share Repurchase Program Business Wire

Sep 23, 2020

06:54AM EDT Eagle Pharma's Partner, SymBio, Receives Approval Of TREAKISYM RTD Formulation, With Launch Expected In January 2021 RTTNews

06:51AM EDT Eagle Pharmaceuticals' Japanese Licensing Partner, SymBio, Receives Approval Of TREAKISYM Ready-To-Dilute Formulation, With Launch Expected In January 2021; Eagle To Receive $5M Milestone Payment Benzinga

06:50AM EDT Eagle Pharmaceuticals' Japanese Licensing Partner, SymBio, Receives Approval of TREAKISYM Ready-To-Dilute ("RTD") Formulation, with Launch Expected in January 2021 Business Wire

Sep 8, 2020

06:50AM EDT Eagle Pharmaceuticals to Present at Upcoming September 2020 Healthcare Conferences Business Wire

Aug 19, 2020

07:00AM EDT Eagle Pharma Announces Publication Of Preclinical Study Of Intranasal Dantrolene In Journal Of Alzheimer's Disease RTTNews

06:51AM EDT Eagle Pharmaceuticals Announces Publication of Preclinical Study of Intranasal Dantrolene in Journal of Alzheimer's Disease Benzinga

Aug 10, 2020

07:18AM EDT Eagle Pharma Q2 Loss Per Share $0.02; Adj EPS $0.59 RTTNews

07:06AM EDT Recap: Eagle Pharmaceuticals Q2 Earnings Benzinga

06:55AM EDT Eagle Pharmaceuticals Q2 EPS $0.57 Beats $0.26 Estimate, Sales $41.90M Miss $42.28M Estimate Benzinga

06:50AM EDT Eagle Pharmaceuticals Reports Second Quarter 2020 Results Business Wire

04:10AM EDT Earnings Scheduled For August 10, 2020 Benzinga

Aug 3, 2020

04:30PM EDT Eagle Pharmaceuticals to Discuss Second Quarter 2020 Financial Results on August 10, 2020 Business Wire

Share